Poland· PL-100040433
Lyxumia
A lixisenatide product containing lixisenatidum, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lixisenatide is registered in 5 of 19 countries.
Countries holding a registration under ATC A10BJ03 (lixisenatide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Lixisenatide · ATC A10BJ03
5 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Polandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Lixisenatidum
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Poland (PL)
- ATC code
- A10BJ03
- ATC class
- Lixisenatide
- Defined daily dose
- 20 mcg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991039806
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
304 interactions on record for lixisenatide.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lixisenatide · interactions on record
304 records
- 3 severe
- 259 moderate
- 42 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lixisenatide in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/33c4c64a-5576-4488-b8f3-ac1ef507c854 GET /v1/drugs/33c4c64a-5576-4488-b8f3-ac1ef507c854?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "10 mcg; 20 mcg",
"packaging": "05909991039806 ¦ Rp ¦ EU/1/12/811/005 ¦ 82131\n1 wstrzykiwacz 3 ml zielony ¦ 1 wstrzykiwacz 3 ml fioletowy",
"substance": "Lixisenatidum 10 mcg (wstrzykiwacz zielony), 20 mcg (wstrzykiwacz fioletowy)",
"common_name": "Lixisenatidum",
"pl_product_id": "100040433",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lixisenatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.